[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624515":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":54,"collaborators":18,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":18,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":18,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Ulm","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Phenotyping Cohort","Patients with Graves' disease and patients with thyroid carcinoma undergoing standard-of-care thyroid treatment.",[12],"Other: Oral Glucose Tolerance Test",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Oral Glucose Tolerance Test","Participants will receive a 75 g oral glucose tolerance (3h) before the start of treatment, two weeks and three months after start of treatment. Body composition will measured by bioimpedance analysis. Before and during the oral glucose tolerance test, indirect calometry will assess metabolic flexibility.",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Martin Heni","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Martin Heni, Prof","CONTACT","+4973150044505","martin.heni@uniklinik-ulm.de",{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},"Roza Sabia, MD","+4973150044719","roza.sabia@uniklinik-ulm.de",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Ulm University Hospital","RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany","DE",{"type":43,"coordinates":44},"Point",[45,46],9.99155,48.39841,{"lat":46,"lon":45},[49,50],{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},{"name":51,"role":26,"phone":52,"phoneExt":18,"email":53},"Sabrina Wangler","+4973150044782","sabrina.wangler@uniklinik-ulm.de",{"type":22,"investigatorFullName":21,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Prof. Dr. med. Martin Heni","100624515","impact-of-thyroid-hormones-on-human-glucose-and-energy-metabolism-100624515",false,"NCT07410637","Impact of Thyroid Hormones on Human Glucose and Energy Metabolism","Inclusion Criteria:\n\n* patients with initial diagnosis of graves disease OR\n* patients with initial diagnosis of thyroid carcinoma\n\nExclusion Criteria:\n\n* contraindications for oral glucose tolerance test\n* Diabetes mellitus\n* Fasting glucose level ≥ 200 mg\u002FdL\n* Exogenous insulin administration with action at the time of the test\n* Current disease with activation of stress hormones\n* Post-aggressive metabolism\n* Acute infectious disease","ALL",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism.\n\nPatients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.",[71,72],"Graves Disease","Thyroid Cancer",[74,75,76,77,78,79],"thyroid hormones","glucose metabolism","lipid metabolism","graves disease","thyroid cancer","hyperthyroidism","2026-02-12",{"date":82,"type":83},"2026-02-13","ACTUAL",{"date":85,"type":83},"2026-02-04",{"date":87,"type":65},"2031-06",{"name":5,"class":6},1]